



PRESS RELEASE Contact: Michael Senken
Phone: (678) 384-6720

MIMEDX GROUP, INC. ANNOUNCES RELEASE DATE FOR 2010 FOURTH QUARTER AND FULL YEAR RESULTS

MARIETTA, Georgia February 23, 2011 (PR Newswire) – MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced today that its results for the fourth quarter and full year ended December 31, 2010, and Company guidance will be released after the closing of the market on Monday, March 28, 2011. The timing of the earnings announcement allows MiMedx time to finalize the required two year audit of its recently acquired subsidiary, Surgical Biologics. The 8K/A filing of the audited financial statements of Surgical Biologics for the fiscal years ended December 31, 2010, and 2009, is due to be filed on Monday March 14, 2011.

MiMedx Group will host a live broadcast of its 2010 results conference call on Tuesday, March 29, 2011, beginning at 10:30 a.m. Eastern Time. A listen-only simulcast of the MiMedx Group conference call will be available online at the Company's website at www.mimedx.com or at www.earnings.com. A 30-day online replay will be available on the Company's website at www.mimedx.com or at .earnings.com approximately one hour following the conclusion of the live broadcast.

About MiMedx

MiMedx is an integrated developer, manufacturer and marketer of patent protected biomaterial-based products and bioimplants processed from human amniotic membrane. The Company is successfully emerging from a development-focused start-up into a fully integrated operating company with an experienced team poised to capitalize on its science and technology to generate sales growth and profitability. Our mantra is "Repair, don't replace" because our biochemists, engineers, designers and physicians believe it is better to augment repair when possible rather than replace traumatized, but otherwise healthy tissues and structures. Our platform technologies, HydroFix™ and CollaFix™, and our newest platform processing technology, Purion®, developed by our wholly-owned subsidiary, Surgical Biologics, have a vast number of potential applications in treating traumatized tissue and structures. MiMedx is focused on commercializing multiple applications for the Company's three technology platforms. In parallel, we are seeking strategic relationships, in selective categories, to accelerate commercialization of our technologies.